Rose Clifford
Psychiatric/Mental Health · Gautier, MSNPI 1730285602
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AbbVie at 57.7% of the total. Reporting peaked in 2023 at $6,707 and has fallen 84.6% since, to $1,031 in 2025. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $31.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$608
- Sunovion Pharmaceuticals Inc.$570
- Johnson & Johnson$567
- Neuronetics, Inc.$547
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$6,18844%
- Travel & lodging$2132%
- Food & beverage$7,55154%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 127 | $8,049 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $1,262 |
| Lundbeck LLC | 30 | $608 |
| Sunovion Pharmaceuticals Inc. | 53 | $570 |
| Johnson & Johnson | 33 | $567 |
| Neuronetics, Inc. | 2 | $547 |
| Axsome Therapeutics, Inc. | 18 | $523 |
| Otsuka America Pharmaceutical, Inc. | 24 | $471 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $304 |
| Alkermes, Inc. | 12 | $224 |
| Supernus Pharmaceuticals, Inc. | 10 | $171 |
| Vanda Pharmaceuticals Inc. | 9 | $166 |
| Corium, LLC | 9 | $152 |
| Teva Pharmaceuticals USA, Inc. | 6 | $114 |
| Idorsia Pharmaceuticals US Inc | 6 | $91 |
| Almatica Pharma LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Tris Pharma Inc | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$6,188
- NEUROSTAR TMS THERAPY SYSTEM$547
- CAPLYTA$372
- Auvelity$247
- SPRAVATO$134
How this compares
$13,959 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 32 | $67,500 |
| VraylarCariprazine Hcl | 37 | $60,991 |
| TrintellixVortioxetine Hydrobromide | 25 | $19,312 |
| Lurasidone Hcl | 29 | $11,747 |
| Quetiapine Fumarate | 162 | $4,997 |
| Trazodone Hcl | 191 | $4,818 |
| Oxcarbazepine | 76 | $3,573 |
| Duloxetine Hcl | 118 | $2,102 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 43 | $1,975 |
| Aripiprazole | 52 | $1,955 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 86 | $1,946 |
| Vilazodone Hcl | 20 | $1,518 |
| Gabapentin | 40 | $1,336 |
| Alprazolam | 126 | $1,274 |
| Escitalopram Oxalate | 114 | $1,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $471 | $67,50032 claims |
| AbbVieVraylar | $8,049 | $60,99137 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $304 | $19,31225 claims |
| Almatica Pharma LLCSertraline Hcl | $76 | $62270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Gautier
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Patrick DuggerOcean Springs$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.